Recruiting

Cogito Platform

Sponsor:

Square2 Systems, Inc.

Code:

NCT07104396

Conditions

Substance Use Disorders (SUDs)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Cogito digital therapeutics development platform

Study Details

Brief summary:

This is a research study to evaluate the usability of the Cogito digital therapeutics development platform.

The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide the components for building a digital therapeutic for any health condition and population.

And in this initial study, the research team plans to examine the usability of Cogito in building a digital therapeutic for substance use disorders (SUDs).

Conditions

Substance Use Disorders (SUDs)

Study ID

NCT07104396

Start date

Jul 2, 2025

Status verified date

Aug, 2025

Completion date

Aug 31, 2025

Anticipated

Primary completion date

Aug 31, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • At least 18 years
  • PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher.
  • Training or trained in substance use disorder (SUDs) research.
  • Must state a specific interest in digital therapeutics for SUDs.

Exclusion Criteria:

  • Those who do not meet inclusion criteria.

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Interventions

Cogito digital therapeutics development platform

Cogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.

Primary outcome measure

  • System Usability Scale [ Time Frame: To be completed immediately after usability feedback session ]

Central Contacts and Locations

Central contacts

Square2 Systems

(802) 526-4608

Locations

Square 2 Systems

Recruiting

Hanover, New Hampshire, United States, 03755

Contacts

Research Coordinator

(802) 526-4608

More Information

Sponsor

Square2 Systems, Inc.

Last update posted

Aug 11, 2025

Last verified

Aug, 2025

Keywords

  • digital therapeutics
  • substance use disorders
  • development platform

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Square2 Systems, Inc. on 2025-08-11.